Pharmalink AB
STOCKHOLM, December 13, 2011 -
Pharmalink AB, today announces it has gained an exclusive global license to Archimedes Pharma Ltd.'s TARGIT drug delivery technology for use in its lead program, Nefecon for the treatment of the kidney disease IgA nephropathy.
STOCKHOLM, October 13, 2010 - Pharmalink AB, a privately held Swedish pharmaceutical
company, has received orphan drug designation by the US Food and Drug
Administration (FDA) for its product candidate Nefecon (PL-56) for patients
with IgA nephropathy, also referred to as Berger's Disease.
STOCKHOLM, June 30, 2010 - Pharmalink AB, today announced that it has closed its
agreement with Grifols SA for the acquisition of Pharmalink's Xepol(R)
programme for the treatment of post-polio syndrome (PPS).
STOCKHOLM -
- Japanese Grant Supports Asian Partnering Programme
Pharmalink AB announced today that it has been granted Japanese Patent No 4326696, "Methods and means for treating glomerulonephritis" for its product Nefecon(R) which is being developed to treat IgA nephropathy, a glomerulonephritis leading to end-stage renal disease (ESRD).
STOCKHOLM, Sweden - Results to be Presented at World Congress of Nephrology 2009
Pharmalink AB announced today that it has completed its open Phase II trial evaluating the efficacy and safety of Nefecon(R) in IgA nephropathy, a glomerulonephritis leading to end-stage renal disease.
